Preterm Premature Rupture Of Membranes between 34 and 37 weeks: EXpectant management versus Induction of Labour

Conditions

Premature rupture of the membranes Pregnancy and Childbirth Premature rupture of the membranes

Annemijn A. de Ruigh, Noor E. Simons, Janneke van ’t Hooft, Aleid G. van Wassenaer‐Leemhuis, Cornelieke S.H. Aarnoudse-Moens et al. (13 authors)

BMJ Open2021-06-017 citations

10.1136/bmjopen-2020-046046

Can neonatal sepsis be predicted in late preterm premature rupture of membranes? Development of a prediction model.

van der Ham DP, van Kuijk S, Opmeer BC, Willekes C, van Beek JJ, Mulder AL, van Loon AJ, Groenewout M, Mantel GD, Bloemenkamp KW, Porath M, Kwee A, Akerboom BM, Papatsonis DN, Metz GC, Nijhuis JG, Mol BW, PPROMEXIL trial group.

2014-02-139 citations

10.1016/j.ejogrb.2014.02.003

Induction of labor versus expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks: a randomized controlled trial.

van der Ham DP, Vijgen SM, Nijhuis JG, van Beek JJ, Opmeer BC, Mulder AL, Moonen R, Groenewout M, van Pampus MG, Mantel GD, Bloemenkamp KW, van Wijngaarden WJ, Sikkema M, Haak MC, Pernet PJ, Porath M, Molkenboer JF, Kuppens S, Kwee A, Kars ME, Woiski M, Weinans MJ, Wildschut HI, Akerboom BM, Mol BW, Willekes C, PPROMEXIL trial group.

2012-04-2474 citations

10.1371/journal.pmed.1001208

Induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the PPROMEXIL-trial).

van der Ham DP, Nijhuis JG, Mol BW, van Beek JJ, Opmeer BC, Bijlenga D, Groenewout M, Arabin B, Bloemenkamp KW, van Wijngaarden WJ, Wouters MG, Pernet PJ, Porath MM, Molkenboer JF, Derks JB, Kars MM, Scheepers HC, Weinans MJ, Woiski MD, Wildschut HI, Willekes C.

2007-07-0629 citations

10.1186/1471-2393-7-11

Interventions

Induction of labour versus expectant management

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Pregnant women with PPROM at a gestational age from 34 + 0/7 until 37 weeks who have given informed consent.

Exclusion criteria

Exclusion criteria: 1. Foetal distress 2. Major foetal anomalies 3. Meconium stained amniotic fluid 4. Maternal infection at entry 5. Monochorionic Diamniotic (MCDA) multiple pregnancy 6. Multiple pregnancy, first child breech presentation 7. Previous caesarean section 8. Diabetes mellitus (defined as use of insulin) 9. Renal disease (inluding Systemic Lupus Erythematosus [SLE]) 10. Seropositive for Human Immunodeficiency Virus (HIV) 11. Haemolysis, Elevated Liver, Low Platelet (HELLP)/severe pre-eclampsia 12. Oliguria less than 500 ml/24 hours

Design outcomes

Primary

Measure	Time frame
Neonatal sepsis	—

Secondary

Measure	Time frame
1. Maternal morbidity (chorioamnionitis/sepsis) 2. Respiratory Distress Syndrome (RDS) 3. Neonatal disease 4. Instrumental delivery rate 5. Quality of life and costs	—

Countries

Netherlands

Outcome results

None listed